- active substance: ciprofloxacin;
- 1 film-coated tablet contains ciprofloxacin 500 mg
- excipients: microcrystalline cellulose, corn starch, crospovidone,
colloidal silicon dioxide, magnesium stearate coating: hypromellose; polyethylene glycol 6000; titanium dioxide (E 171).
Dosage form. Film-coated tablets.
10 tablets in a blister; 1 blister in a cardboard box.
Ciprofloxacin is indicated for the treatment of the following bacterial infections caused by susceptible pathogens.
Lower respiratory tract infections caused by gram-negative bacteria:
- exacerbation of chronic obstructive pulmonary disease;
- bronchopulmonary infections in cystic fibrosis or bronchiectasis;
Chronic purulent otitis media.
Exacerbation of chronic sinusitis, especially if it is caused by gram-negative bacteria.
Urinary tract infections.
Infectious lesions of the genital system:
- gonococcal urethritis and cervicitis caused by sensitive strains of Neisseria gonorrhea;
- orchoepididymitis , in particular, caused by susceptible strains of Neisseria gonorrhoeae;
inflammatory diseases of the pelvic organs, in particular caused by sensitive strains of Neisseria gonorrhoeae.
Digestive tract infections (such as traveler’s diarrhea).
Skin and soft tissue infections are caused by gram-negative bacteria.
Severe otitis externa.
Bone and joint infections.
Prevention of invasive infections caused by Neisseria meningitides.
The pulmonary form of anthrax (prevention after contact and radical treatment).
Ciprofloxacin can be used for the management of patients with neutropenia and hyperthermia in case of suspicion of fever of bacterial infectious origin in this category of patients.
The tablets should be swallowed without chewing, washed down with liquid. They can be taken with or without food. When taken on an empty stomach, the active substance is absorbed faster. Ciprofloxacin tablets should not be taken with dairy products (eg milk, yogurt) or fruit juices with added minerals (eg orange juice enriched with calcium) (see section “Interaction with other medicinal products and other forms of interaction”).
In severe cases or in case of inability of the patient to take tablets (especially with enteral nutrition), it is recommended to start therapy with intravenous ciprofloxacin until it is possible to switch to oral administration.
Ciprofloxacin in children should be administered in accordance with current official guidelines. Treatment with ciprofloxacin should be performed by a physician experienced in the management of children and adolescents with cystic fibrosis and/or severe infections.
Ciprofloxacin caused arthropathy of the supporting joints in immature animals.
Treatment of children with ciprofloxacin should be initiated only after careful evaluation of the corrosion / risk ratio due to the possible risk of adverse reactions associated with joints and/or surrounding tissues.